Electrical Stimulation for the Treatment of Optic Neuropathies

Stanford University40 enrolled

Overview

The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.

This is a concurrent open-label study for patients who are deemed safe to participate in the electrical stimulation trial but do not fit the exact criteria for the randomized clinical trial.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glaucoma Glaucoma, Open-Angle Optic Nerve Diseases

Interventions

Repetitive, Transorbital Alternating Current Stimulation (rtACS)DEVICE

Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participant must be at least 18. 2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE). 3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false postivies do not exeed 20%. 4. In the opinion of the investigator the participant's eye pressure must be clinically stable. 5. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study. 6. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety. Exclusion Criteria: 1. Participant is unable to comply with study procedures or follow-up visits. 2. Participant has a history of ocular herpes zoster. 3. Participant has pathological nystagmus 4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa. 5. Participant has evidence of corneal opacification or lack of optical clarity. 6. Participant has uveitis or other ocular inflammatory disease. 7. Participant has any electric or electroinc implants such as a pacemaker. 8. Participant has acute conjunctivitis. 9. Participant has acute autoimmune disease. 10. Participant is pregnant or lactating. 11. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia. 12. Unresected brain tumors 13. Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable 14. Patients with any skin damage. 15. Children and comatose patients. 16. Patients with history of epileptic seizure within the last 10 years. 17. Patients with uncontrolled systemic hypertension or uncontrolled diabetes. 18. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation 19. Prior participation in a vision training/stimulation study in the last 12 months

Locations (1)

Byers Eye Institute

Palo Alto, California, United States

RECRUITING

Outcomes

Primary Outcomes

Change from baseline in visual field assessed by Humphrey Visual Field Index (VFI).

Time frame: Baseline through 6 months

Change from baseline in visual field assessed by Humphrey Mean Deviation (MD).

Time frame: Baseline through 6 months

Secondary Outcomes

Change from baseline in ganglion cell layer as measured by optical coherence tomography (OCT, visible light and/or infrared).

Time frame: Baseline through 6 months

Change from baseline in nerve fiber layer thickness as measured by optical coherence tomography (OCT, visible light and/or infrared).

Time frame: Baseline through 6 months

Change from baseline in visual acuity as assessed by the Snellen visual acuity test.

The Snellen test is a standard eye chart test used to test eyesight.

Time frame: Baseline through Month 6

Change from baseline in visual evoked potential.

Time frame: Baseline through Month 6

Change from baseline in retinal metabolic analysis(RMA)/OcuMet imaging.

There are two index measures of retinal metabolism and a normative database; change from baseline with a statistically significant difference from test-retest variability will be the exploratory endpoint measured here.

Time frame: Baseline through Month 6

Change from baseline in adaptive optics retinal imaging.

There are no index measures for adaptive optics retinal imaging in this disease; change from baseline will be the exploratory endpoint measured here.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.